Launch of 20 new medicines expected by 2030
Significant growth from existing oncology, biopharmaceuticals and rare disease portfolios
Investing in disruptive innovation that will shape the future.
Can a CEO be worth $9 billion? Without a clear succession plan, investors should prepare for further swings. Today AstraZeneca’s shares are worth nearly twice that amount, and the group has thrived thanks to blockbusters like breast cancer treatment Lynparza, and bold M&A, such as the $39 billion purchase of rare disease specialist Alexion in the middle of the pandemic.
VÄLISMAA KOROONAPÄEVIK ⟩ Taani peatas AstraZeneca vaktsiini kasutamise ja Läti terviseminister taotleb riigi sulgemist - Maailm - Postimees ee postimees.ee - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from postimees.ee Daily Mail and Mail on Sunday newspapers.